Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Rosetta Genomics Ltd. (Nasdaq: ROSG), an innovative molecular diagnostic company, today announced the execution of ...
Addressing obviousness issues, the U. S. Court of Appeals for the Federal Circuit affirmed the district court’s invalidity conclusion, agreeing that the elements present in the prior art—including ...
Case Name: Prometheus Labs, Inc. v. Roxane Labs, Inc., Case Nos. 11-230 (FSH), 11-1241 (FSH), Unpublished (D.N.J. May 21, 2014) (Hochberg, J.) Drug Product and Patent ...
@JohnCFierce: Derek Lowe explains in concise terms why BioTime's cell aging work has a long, long way to go. Item | Follow @JohnCFierce > Prometheus Laboratories struck a deal to collaborate with ...
Prometheus Laboratories Inc., (“Prometheus”) a specialty pharmaceutical and diagnostic company, today announced that it has entered into a definitive agreement to be acquired by Nestle Health Science ...
San Diego-based Prometheus Laboratories, a specialty pharma and diagnostics company, has filed an amendment to its plans for an initial public offering, which has been in registration for nearly three ...
Firm’s newly established business will use purchase to move into gastrointestinal testing. Nestlé’s recently established Nestlé Health Science operation will acquire specialty pharmaceutical and ...
NEW YORK, Nov 7 (Reuters) - Privately held Prometheus Laboratories Inc said on Wednesday it has agreed to acquire exclusive U.S. rights to GlaxoSmithKline's irritable bowel syndrome drug Lotronex.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback